

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/33676> holds various files of this Leiden University dissertation.

Author: Huis-Tanja, Lieke Henriëtte van

Title: Pharmacogenetics of capecitabine and oxaliplatin in treatment of advanced colorectal cancer

Issue Date: 2015-06-23

Pharmacogenetics of capecitabine and oxaliplatin in treatment of advanced colorectal cancer

Lieke van Huis–Tanja

**Pharmacogenetics of capecitabine and oxaliplatin
in treatment of advanced colorectal cancer**

© 2015 L.H. van Huis – Tanja, the Netherlands

ISBN 978-94-92026-04-0

Cover design: Esther Ris, www.proefschriftomslag.nl

Layout: Esther Ris, www.proefschriftomslag.nl

Printed by: Gildeprint, www.gildeprint.nl

No part of this thesis may be reproduced in any form or by any means without written permission of the author or of the publisher holding the copyright of the published articles.

The printing of this thesis was financially supported by:
AZL Onderzoeks- en Ontwikkelingskrediet (OOK) Apotheek.

Pharmacogenetics of capecitabine and oxaliplatin in treatment of advanced colorectal cancer

Proefschrift

Ter verkrijging van
de graad van doctor aan de Universiteit van Leiden,
op gezag van de Rector Magnificus prof. mr. C.J.J.M. Stolker
volgens besluit van het College voor Promoties
te verdedigen op 23 juni 2015
klokke 16.15 uur

door

Lieke Henriëtte van Huis – Tanja
Geboren te Heerlen
in 1979

Promotiecommissie

Promotores

Prof. Dr. H.-J. Guchelaar
Prof. Dr. A.J. Gelderblom

Co-promotor

Dr. D.M. Kweekel

Manuscriptcommissie

Prof. Dr. J.W.R. Nortier
Prof. Dr. J.H.Schellens
Netherlands Cancer Institute Antoni van Leeuwenhoek
Prof. Dr. R.A. Tollenaar

Contents

1. Introduction to this thesis	7
General pharmacogenetic considerations	
2. Pharmacogenetics in chemotherapy of colorectal cancer <i>Best Pract Res Clin Gastroenterol. 2009;23(2):257-73</i>	13
3. Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples <i>Pharmacogenomics. 2013 Dec;14(16):2005-12</i>	37
Pathway-based approach	
<u>Capecitabine</u>	
4. <i>MTHFR</i> polymorphisms and capecitabine-induced toxicity in metastatic colorectal cancer patients <i>Pharmacogenet Genomics. 2013 Apr;23(4):208-18</i>	51
5. Clinical validation study of genetic markers for capecitabine efficacy in metastatic colorectal cancer patients <i>Pharmacogenet Genomics. 2015 Jun;25(6):279-88</i>	79
<u>Oxaliplatin</u>	
6. Effects of genetic variation in organic cation transporters (<i>OCT</i>) on oxaliplatin-induced neurotoxicity	97
7. Excision Repair Cross-Complementation group 1 (<i>ERCC1</i>) C118T SNP does not affect cellular response to oxaliplatin <i>Mutat Res Fundam Mol Mech Mutagen. 2014 Jan;759:37-44</i>	113
Genome wide approach	
8. Genome wide association study for predictors of progression free survival on capecitabine, oxaliplatin and bevacizumab in first-line therapy of metastatic colorectal cancer <i>PlosOne, accepted for publication</i>	133
General discussion and summary	
9. General discussion and future research	149
Summary	162
Nederlandse samenvatting	164
Curriculum vitae	166
List of publications	167
Dankwoord	168

